Mediolanum International Funds Ltd trimmed its stake in shares of Medtronic plc (NYSE:MDT – Free Report) by 3.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 292,515 shares of the medical technology company’s stock after selling 9,714 shares during the period. Mediolanum International Funds Ltd’s holdings in Medtronic were worth $26,084,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Lynx Investment Advisory acquired a new stake in Medtronic in the second quarter valued at approximately $28,000. Tributary Capital Management LLC acquired a new stake in Medtronic in the first quarter valued at approximately $33,000. Gleason Group Inc. acquired a new stake in Medtronic in the second quarter valued at approximately $42,000. Opal Wealth Advisors LLC acquired a new stake in Medtronic in the second quarter valued at approximately $43,000. Finally, Olistico Wealth LLC acquired a new stake in Medtronic in the second quarter valued at approximately $45,000. 82.06% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several analysts have commented on the company. Citigroup raised their price objective on Medtronic from $85.00 to $92.00 and gave the company a “neutral” rating in a report on Tuesday, October 1st. Robert W. Baird raised their target price on Medtronic from $82.00 to $90.00 and gave the company a “neutral” rating in a research report on Wednesday, August 21st. Royal Bank of Canada upgraded Medtronic from a “sector perform” rating to an “outperform” rating and raised their target price for the company from $98.00 to $105.00 in a research report on Thursday, October 10th. Barclays raised their target price on Medtronic from $104.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, August 22nd. Finally, Stifel Nicolaus raised their target price on Medtronic from $85.00 to $87.00 and gave the company a “hold” rating in a research report on Wednesday, August 21st. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Medtronic has an average rating of “Hold” and an average target price of $95.36.
Medtronic Stock Performance
MDT traded down $0.07 on Friday, hitting $90.92. 805,106 shares of the company traded hands, compared to its average volume of 6,202,194. The company has a 50 day moving average of $89.04 and a 200-day moving average of $83.74. The company has a quick ratio of 1.61, a current ratio of 2.13 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $116.60 billion, a PE ratio of 30.54, a PEG ratio of 2.60 and a beta of 0.84. Medtronic plc has a 12-month low of $68.84 and a 12-month high of $92.68.
Medtronic (NYSE:MDT – Get Free Report) last released its earnings results on Tuesday, August 20th. The medical technology company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.03. Medtronic had a return on equity of 13.68% and a net margin of 12.06%. The company had revenue of $7.97 billion for the quarter, compared to analysts’ expectations of $7.90 billion. During the same quarter in the previous year, the firm posted $1.20 EPS. The firm’s quarterly revenue was up 3.4% on a year-over-year basis. Sell-side analysts anticipate that Medtronic plc will post 5.44 earnings per share for the current year.
Medtronic Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Friday, October 11th. Shareholders of record on Friday, September 27th were issued a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a yield of 3.08%. The ex-dividend date of this dividend was Friday, September 27th. Medtronic’s dividend payout ratio (DPR) is presently 94.59%.
Medtronic Company Profile
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Featured Articles
- Five stocks we like better than Medtronic
- Stock Market Sectors: What Are They and How Many Are There?
- Texas Roadhouse Stock Steering for New Highs This Year
- How to Use the MarketBeat Excel Dividend Calculator
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How Can Investors Benefit From After-Hours Trading
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.